Literature DB >> 9593159

Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC.

F J Schmitz1, M E Jones, B Hofmann, B Hansen, S Scheuring, M Lückefahr, A Fluit, J Verhoef, U Hadding, H P Heinz, K Köhrer.   

Abstract

One hundred sixteen unrelated clinical isolates of Staphylococcus aureus (70 ciprofloxacin resistant and 46 ciprofloxacin susceptible) from eight countries were studied for the presence of mutations in the grlA, grlB, gyrA, and gyrB gene loci. Two mutations within grlA (located at codons 80 and 84) and two mutations within gyrA (located at codons 84 and 88) were clearly associated with ciprofloxacin resistance, although other mutations detected within the four genes studied may also contribute to decreased susceptibility.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9593159      PMCID： PMC105791          DOI： 10.1128/AAC.42.5.1249

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus.

Authors:  M Takahata; M Yonezawa; S Kurose; N Futakuchi; N Matsubara; Y Watanabe; H Narita
Journal:  J Antimicrob Chemother       Date:  1996-09       Impact factor: 5.790

2.  Cloning, sequencing, and expression of the DNA gyrase genes from Staphylococcus aureus.

Authors:  S M Brockbank; P T Barth
Journal:  J Bacteriol       Date:  1993-06       Impact factor: 3.490

3.  Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus.

Authors:  J Yamagishi; T Kojima; Y Oyamada; K Fujimoto; H Hattori; S Nakamura; M Inoue
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

4.  Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.

Authors:  E Y Ng; M Trucksis; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

5.  Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.

Authors:  L Ferrero; B Cameron; B Manse; D Lagneaux; J Crouzet; A Famechon; F Blanche
Journal:  Mol Microbiol       Date:  1994-08       Impact factor: 3.501

Review 6.  Epidemiology of quinolone resistance: Europe and North and South America.

Authors:  F W Goldstein; J F Acar
Journal:  Drugs       Date:  1995       Impact factor: 9.546

7.  Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus.

Authors:  H Ito; H Yoshida; M Bogaki-Shonai; T Niga; H Hattori; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

8.  Inducible NorA-mediated multidrug resistance in Staphylococcus aureus.

Authors:  G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

9.  Nucleotide sequence of the Staphylococcus aureus gyrB-gyrA locus encoding the DNA gyrase A and B proteins.

Authors:  E E Margerrison; R Hopewell; L M Fisher
Journal:  J Bacteriol       Date:  1992-03       Impact factor: 3.490

10.  Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus.

Authors:  L Ferrero; B Cameron; J Crouzet
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191
View more
  49 in total

1.  Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones.

Authors:  S Brisse; A C Fluit; U Wagner; P Heisig; D Milatovic; J Verhoef; S Scheuring; K Köhrer; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

2.  Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season.

Authors:  M E Jones; D F Sahm; N Martin; S Scheuring; P Heisig; C Thornsberry; K Köhrer; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

3.  In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.

Authors:  M Boos; S Mayer; A Fischer; K Köhrer; S Scheuring; P Heisig; J Verhoef; A C Fluit; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

4.  Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance.

Authors:  D E Low; M Muller; C L Duncan; B M Willey; J C de Azavedo; A McGeer; B N Kreiswirth; S Pong-Porter; D J Bast
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

Review 5.  Molecular detection of antimicrobial resistance.

Authors:  A C Fluit; M R Visser; F J Schmitz
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

6.  In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants.

Authors:  Ad C Fluit; Franz-Josef Schmitz; Jan Verhoef; Dana Milatovic
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

7.  The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.

Authors:  Sachin S Bhagwat; Lakshmi A Mundkur; Shrikant V Gupte; Mahesh V Patel; Habil F Khorakiwala
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

8.  In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.

Authors:  Brian J Morrow; Wenping He; Karen M Amsler; Barbara D Foleno; Mark J Macielag; A Simon Lynch; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

9.  Real-time PCR assay for detection of fluoroquinolone resistance associated with grlA mutations in Staphylococcus aureus.

Authors:  Pascal Lapierre; Ann Huletsky; Véronique Fortin; François J Picard; Paul H Roy; Marc Ouellette; Michel G Bergeron
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

10.  Quinolone resistance mutations in the GrlB protein of Staphylococcus aureus.

Authors:  M Tanaka; Y Onodera; Y Uchida; K Sato
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.